Search - tctmd.com

Displaying 101 - 120 of 159

Sort: Relevancy | Date

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Presenter: John A. Bittl, Robert A. Harrington, Jorge F. Saucedo

October 12, 2015

Presentation TCT 2015

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Presenter: John A. Bittl, Robert A. Harrington, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2015

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

Presenter: Spencer B. King III, Jagat Narula, James B. Hermiller Jr

October 12, 2015

Presentation TCT 2015

Debate: The Case for Short-term DAPT in Most Patients!

Presenter: Regina Deible, Gennaro Giustino

October 11, 2015

Presentation TCT 2015

Debate: The Case for Long-term DAPT After Stenting In Most Patients!

Presenter: Regina Deible, Daniel I. Simon

October 11, 2015

Presentation TCT 2015

Introduction: Why Is This Issue Important? Ischemia vs Bleeding

Presenter: Regina Deible, Roxana Mehran

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Presenter: C. Michael Gibson, Marco Valgimigli, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation ESC 2015

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Presenter: Jacob A. Udell

August 31, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

Presentation

Left Main or Proximal LAD (LM-pLAD) Coronary Artery Disease Location Identifies High-Risk Pts Deriving Potentially Greater Benefit From Prolonged Dual Antiplatelet Therapy (DAPT)

Presenter: F. Costa

August 21, 2015

Presentation

Mortality in Pts Treated With Extended Duration Dual Antiplatelet Therapy (DAPT) After DES

Presenter: T. Palmerini

March 18, 2015

Presentation

Short- vs Long-term Dual Antiplatelet Therapy After DES Implantation

Presenter: T. Palmerini

March 18, 2015

Presentation

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Presenter: Gregg W. Stone

December 01, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Advertisement

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

Debate: The Case for Short-term DAPT in Most Patients!

Debate: The Case for Long-term DAPT After Stenting In Most Patients!

Introduction: Why Is This Issue Important? Ischemia vs Bleeding

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Left Main or Proximal LAD (LM-pLAD) Coronary Artery Disease Location Identifies High-Risk Pts Deriving Potentially Greater Benefit From Prolonged Dual Antiplatelet Therapy (DAPT)

Mortality in Pts Treated With Extended Duration Dual Antiplatelet Therapy (DAPT) After DES

Short- vs Long-term Dual Antiplatelet Therapy After DES Implantation

AHA 2014 Late Breaking Trials: Duration of Dual Anti-platelet Therapy after Stenting

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content